The CEO of Pfizer confirms that quizas needed a third dose to boost the vaccine

A complete pandemic for the new coronavirus that generated the enforced COVID-19, the all-in-one vacation campaign this week, with logic problematic of the evacuation of vacancies which exists in the market and the agreements between countries for the distribution of the doses.

In this scenario and meanwhile the United States will be launching the massive application of vacancies against the coronavirus SARS-CoV-2, including a new record of daily applications with 4.6 million injections applied during the day, the Pfizer CEO, Albert Bourla, admitting that it is possible that a third dose is needed in the year of vacancy with the initials dose.

Pfizer issued a statement outlining its principles in a statement issued its vaccine against COVID-19 was effective up to 91% to protect against the new coronavirus and more than 95% effective against severe infections up to 6 months after the second dose. The dates of Pfizer’s bazaar and more than 12,000 participants vacunados. However, investigators say that more data are needed to determine whether the protections are more than 6 months old. Investigators have not been able to see for some time during the protection period that some have been completely evacuated.

David Kessler, COVID’s Director of Response at the COVID Administration, stated that the estadounidenses deberían hope to receive refurbishment injections to protect against coronavirus variants. Kessler has warned state legislators and demonstrators that vacancies are currently being protected altogether, but signaled that new variants could “challenge” the effectiveness of injections.

“No sabemos do it. We are studying the durability of the response of the anticursors ”, dijo. ‘Forced to fly, but haoi algo de declive y sin duda las variants desafían … hacen que estas vacunas funcionen más. If there is room for planning, only with planning, we will have to hope that we will get impulse, ”said the Select Subcommittee of the Chamber on Response to Coronavirus.

In February, Pfizer and BioNTech say they are considering a third dose of their COVID-19 vaccine to better understand the immune response against new variants of the virus. In recent months, the National Institutes of Health has announced that it will try a new modern-day vaccine to protect against a problematic variant found in South Africa. Y Pfizer-BioNTech is trying to get a new injection of its COVID vaccine in a new attempt to better understand the immune response against new variants of the virus.

También is in talks with the regulatory authorities about trying a modified vehicle to protect specifically against the new highly transmissible variant found in South Africa and other places, known as B.1.351, as a good second of the same.

The companies claim that their current dose range is working against the South African variant, as well as against one that is found in the United Kingdom and in other places. But the studios allow the manufacturers of vacancies to be prepared when they need more protection, dijeron. “The case of mutations in the actual virus is the highest of the hoped-for,” said Pfizer Scientific Director Mikael Dolsten in an interview. ‘This is a probable reason that we end up with regular increases. And for the potential vacancies, it is possible to have a change of heart every year, but not necessarily all the years, ”he said.

During the first stage of the study’s first, a third dose of 30 micrograms is administered to 144 people who receive the vaccine 6 to 12 months ago in the original Phase I safety unit. “Subject to regulatory approval, a redesigned vaccine is also being tested, as well as a dose of refunds for people who have been vaccinated as for persons who have not received the vaccine,” said Dolsten.

The study does not show the vaccine efficacy as its major phase III trial this year. In addition, the anticonvulsant and study response is mediated by the ability of the receptors to neutralize the new coronavirus variants, as well as the security of a third dose. United States has discovered its first case of the South African variant in January and has since appeared in 14 states, según datos del gobierno estadounidense. Various studies suggest that it is more resistant to existing vacancies than other coronavirus variants.

Dolsten points out that ARNm’s vacancies like Pfizer’s and BioNTech’s vacancy create a potent response. Peru the response can be reduced with time. Tambié creates that a third dose of his vaccine will create a response similar to the best of the second dose, and can be the next logical step to maintain by performing the circulating variants.

“We believe that our vaccine is very active against all diseases”, said Dolsten, and signaled that companies “should be prepared for all the options and be impulsed by the dates, led by science”.

SEGUIR LEYENDO: